International Ophthalmology

, Volume 28, Issue 1, pp 59–61 | Cite as

Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma

Case Report

Abstract

Background Intravitreal injections of bevacizumab have been reported to have anatomical and functional success in treating choroidal neovascularization, macular edema and neovascular glaucoma. We report a case with neovascular glaucoma due to central retinal vein occlusion who demonstrates rapid resolution of anterior and posterior segment neovascularization after a single intravitreal bevacizumab injection. Case A 46-year old man with a 6-month history of central retinal vein occlusion presented with neovascular glaucoma. Fluorescein angiography revealed marked leakage from new vessels on the iris, disc and retina. Bevacizumab was used after incomplete panretinal photocoagulation because of inadequate fundus visualization. About a week after intravitreal bevacizumab injection, new vessels were no longer visible. IOP improved and additional laser photocoagulation was performed. Conclusion Intravitreal bevacizumab injection may be a useful alternative or adjuvant treatment for patients with neovascular glaucoma in whom inadequate visualization precludes adequate panretinal photocoagulation.

Keywords

Central retinal vein occlusion Intravitreal bevacizumab Neovascular glaucoma 

References

  1. 1.
    Ferrara N (2004) Vascular endothelial growth factor: basic science in clinical progress. Endocrinol Rev 25:581–611CrossRefGoogle Scholar
  2. 2.
    Kabbinavar E, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV)with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65PubMedCrossRefGoogle Scholar
  3. 3.
    Michels S, Rosenfeld PJ, Puliafito CA et al (2005) Systemic bevacizumab (Avastin) for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label therapy. Ophthalmology 36:270–271Google Scholar
  4. 4.
    Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335PubMedGoogle Scholar
  5. 5.
    Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers and Imaging 36:336–339Google Scholar
  6. 6.
    Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment. Retina 26:352–354PubMedCrossRefGoogle Scholar
  7. 7.
    Kahook MY,Schuman JS,Noecker RJ (2006) Intravitreal Bevacizumab in a patient with Neovascular Glaucoma. Ophthalmic Surg Laser Imaging 37(2):144–146Google Scholar
  8. 8.
    Fernandez-Vigo J, Castro J, Macarro A (1997) Diabetic iris neovascularization. Natural history and treatment. Acta Ophthalmol Scand 75:89–93PubMedCrossRefGoogle Scholar
  9. 9.
    Adamis PA, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111–118PubMedCrossRefGoogle Scholar
  10. 10.
    Silva Paula J, Jorge R, Alves Costa R, Lourdes M, Rodrigues V, Scott IU (2006) Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmologica Scand 84(4):556–557CrossRefGoogle Scholar
  11. 11.
    Mason JO, Albert MA, Mays A, Vail R (2006) Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26(7):839–841PubMedCrossRefGoogle Scholar
  12. 12.
    Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM (2006) Intravitreal Bevacizumab (Avastin) in the treatment of Neovascular Glaucoma. Am J Ophthalmol 142(6):1054–1056PubMedCrossRefGoogle Scholar
  13. 13.
    Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU (2006) Intracameral Bevacizumab for iris rubeosis. Am J Ophthalmol 142(1):158–160 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  1. 1.Department of OphthalmologyAnkara University School of MedicineDikimeviTurkey

Personalised recommendations